UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________to______________________ Commission File Number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charter) Florida 26-27925 ...

| --- | --- | --- | |------------------------------------------------------------|-------------------------------|-------| | | | | | | | | | MiMedx | | | | ADVANCED PLACENTAL SCIENCE March 9-10, 2021 | INNOVATING TREATMENTS THROUGH | | | 2021 H.C. Wainwright & Co. Global Life Sciences Conference | | | IMPORTANT CAUTIONARY STATEMENT This presentation contains forward-looking statements. Actual results may differ materially. Investors are cautioned against placing undue reliance on these statements, All state ...

MiMedx Group, Inc. (NASDAQ:MDXG) Q4 2020 Earnings Conference Call March 8, 2021 9:30 AM ET Company Participants Jack Howarth - VP of IR and Corporate Communications Tim Wright - CEO Pete Carlson - CFO Robert Stein - EVP, Research & Development Rohit Kashyap - EVP and Chief Commercial Officer Conference Call Participants Sean Kang - H.C. Wainwright John Vandermosten - SIC Zacks Eiad Asbahi - Prescience Point Operator Ladies and gentlemen, thank you for standing by, and welcome to the MiMedx Fourth Quarter 20 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to __________ Commission file number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

| --- | --- | --- | |-------------------------------------------------------------------------------|-------|-------| | | | | | INNOVATING TREATMENTS THROUGH ADVANCED PLACENTAL SCIENCE January 11-14, 2021 | | | | 2021 J.P. Morgan 39th Annual Healthcare Conference | | | IMPORTANT CAUTIONARY STATEMENT This presentation contains forward-looking statements. Investors are cautioned against placing undue reliance on these statements. All statements relating to events or results that may occur in the future are fo ...

MiMedx Group, Inc. (NASDAQ:MDXG) Q3 2020 Earnings Conference Call November 5, 2020 8:30 AM ET Company Participants Hilary Dixon - VP of IR and Corporate Communications Tim Wright - Chief Executive Officer Pete Carlson - Chief Financial Officer Bob Stein - Executive VP, Research & Development Rohit Kashyap - Executive Vice President and Chief Commercial Officer Conference Call Participants Eiad Asbahi - Prescience Point. Brian Finn - FIN Capital Operator Ladies and gentlemen, thank you for standing by and we ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________to______________________ Commission File Number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charter) Florida 26-2 ...

MiMedx Group, Inc. (NASDAQ:MDXG) Q2 2020 Earnings Conference Call August 11, 2020 8:30 AM ET Company Participants Hilary Dixon - VP of IR and Corporate Communications Tim Wright - CEO Pete Carlson - CFO Conference Call Participants Eiad Asbahi - Prescience Point Capital Management Brian Finn - FIN Capital Operator Good morning and welcome to the MiMedx Second Quarter 2020 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________to______________________ Commission File Number 001-35887 MIMEDX GROUP, INC. | | | Name of each exchange on which | | --- | --- | --- | | Title of ea ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________to______________________ Commission file number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charter) (State or ot ...